利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

75 条记录 (耗时 0.024 秒)

    Therapeutic Agent for infections, and treatment method using the same
    2.
    发明申请
    Therapeutic Agent for infections, and treatment method using the same 审中-公开
    用于感染的治疗剂，以及使用其的治疗方法

    公开(公告)号：US20130011366A1

    公开(公告)日：2013-01-10

    申请号：US13604645

    申请日：2012-09-06

    申请人： Masaji Okada ,  Yasushi Takamori ,  Kazuyuki Ogawa ,  Kinya Nagata

    发明人： Masaji Okada ,  Yasushi Takamori ,  Kazuyuki Ogawa ,  Kinya Nagata

    IPC分类号： A61K38/17 ,  A61P31/06 ,  C12N15/63 ,  A61K38/20 ,  A61K48/00

    CPC分类号： A61K38/20 ,  A61K38/164 ,  A61K38/1709 ,  A61K38/1729 ,  A61K38/204 ,  A61K38/208 ,  A61K39/04 ,  A61K2300/00

    摘要： (Problems)To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same.(Means for solving problems)The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo expression vector and at least one interleukin selected from IL-6, IL-23 or IL-27, or a combination of 15K granulysin in vivo expression vector and HSP65DNA and IL-12DNA in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.

    摘要翻译： （问题）为了提供包含颗粒溶素作为活性成分的感染治疗剂，其副作用小，无细胞毒性，细菌几乎不能获得抗性，以及使用该治疗剂的治疗方法。 （解决问题的手段）本发明提供一种感染用治疗剂，其包含作为活性成分的15K颗粒溶素，15K颗粒溶素和15K颗粒溶素在体内表达载体的组合，15K颗粒溶素与至少一种选自IL- 6，IL-23或IL-27，15K颗粒溶素在体内表达载体和选自IL-6，IL-23或IL-27中的至少一种白介素或15K颗粒溶素的体内表达载体和HSP65DNA的组合的组合 和IL-12DNA体内表达载体，其对细菌的杀伤作用增强，副作用较小，细菌几乎不能获得抗性，以及使用其的处理方法。

    Therapeutic agent for infections, and treatment method using the same
    3.
    发明授权
    Therapeutic agent for infections, and treatment method using the same 有权
    用于感染的治疗剂和使用其的治疗方法

    公开(公告)号：US08288509B2

    公开(公告)日：2012-10-16

    申请号：US12386974

    申请日：2009-04-24

    申请人： Masaji Okada ,  Yasushi Takamori ,  Kazuyuki Ogawa ,  Kinya Nagata

    发明人： Masaji Okada ,  Yasushi Takamori ,  Kazuyuki Ogawa ,  Kinya Nagata

    IPC分类号： A61K39/00 ,  A61K39/38 ,  A61K38/00 ,  C07K16/00 ,  C07K17/00 ,  C07K5/00 ,  C07K7/00 ,  C07K14/00

    CPC分类号： A61K38/20 ,  A61K38/164 ,  A61K38/1709 ,  A61K38/1729 ,  A61K38/204 ,  A61K38/208 ,  A61K39/04 ,  A61K2300/00

    摘要： (Problems)To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same.(Means for Solving Problems)The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo expression vector and at least one interleukin selected from IL-6, IL-23 or IL-27, or a combination of 15K granulysin in vivo expression vector and HSP65DNA and IL-12DNA in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.

    摘要翻译： （问题）为了提供包含颗粒溶素作为活性成分的感染治疗剂，其副作用小，无细胞毒性，细菌几乎不能获得抗性，以及使用该治疗剂的治疗方法。 （解决问题的手段）本发明提供一种感染治疗剂，其包含15K颗粒溶素，15K颗粒溶素和15K颗粒溶素在体内表达载体的组合，15K颗粒溶素与至少一种选自IL- 6，IL-23或IL-27，15K颗粒溶素在体内表达载体和选自IL-6，IL-23或IL-27中的至少一种白介素或15K颗粒溶素的体内表达载体和HSP65DNA的组合的组合 和IL-12DNA体内表达载体，其对细菌的杀伤作用增强，副作用较小，细菌几乎不能获得抗性，以及使用其的处理方法。

    Therapeutic agent for infections, and treatment method using the same
    4.
    发明申请
    Therapeutic agent for infections, and treatment method using the same 有权
    用于感染的治疗剂和使用其的治疗方法

    公开(公告)号：US20090274651A1

    公开(公告)日：2009-11-05

    申请号：US12386974

    申请日：2009-04-24

    申请人： Masaji Okada ,  Yasushi Takamori ,  Kazuyuki Ogawa ,  Kinya Nagata

    发明人： Masaji Okada ,  Yasushi Takamori ,  Kazuyuki Ogawa ,  Kinya Nagata

    IPC分类号： A61K38/20 ,  C07K14/47 ,  A61K38/16 ,  A61K31/711 ,  A61P31/06

    CPC分类号： A61K38/20 ,  A61K38/164 ,  A61K38/1709 ,  A61K38/1729 ,  A61K38/204 ,  A61K38/208 ,  A61K39/04 ,  A61K2300/00

    摘要： (Problems) To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same. (Means for Solving Problems) The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo expression vector and at least one interleukin selected from IL-6, IL-23 or IL-27, or a combination of 15K granulysin in vivo expression vector and HSP65DNA and IL-12DNA in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.

    摘要翻译： （问题）为了提供包含颗粒溶素作为活性成分的感染治疗剂，其副作用小，无细胞毒性，细菌几乎不能获得抗性，以及使用该治疗剂的治疗方法。 （解决问题的手段）本发明提供一种感染治疗剂，其包含15K颗粒溶素，15K颗粒溶素和15K颗粒溶素在体内表达载体的组合，15K颗粒溶素与至少一种选自IL- 6，IL-23或IL-27，15K颗粒溶素在体内表达载体和选自IL-6，IL-23或IL-27中的至少一种白介素或15K颗粒溶素的体内表达载体和HSP65DNA的组合的组合 和IL-12DNA体内表达载体，其对细菌的杀伤作用增强，副作用较小，细菌几乎不能获得抗性，以及使用其的处理方法。

    THERAPEUTIC AGENT FOR INFECTIONS, AND TREATMENT METHOD USING SAME
    5.
    发明申请
    THERAPEUTIC AGENT FOR INFECTIONS, AND TREATMENT METHOD USING SAME 有权
    用于感染的治疗剂，以及使用相同的治疗方法

    公开(公告)号：US20140308240A1

    公开(公告)日：2014-10-16

    申请号：US14292940

    申请日：2014-06-02

    申请人： MASAJI OKADA (27%) ,  YASUSHI TAKAMORI (20%) ,  NATIONAL HOSPITAL ORGANIZATION, KINKI-CHUO CHEST MEDICAL CENTER (27%) ,  AZBIO CORPORATION (26%)

    发明人： Masaji Okada ,  Yasushi Takamori ,  Kazuyuki Ogawa ,  Kinya Nagata

    IPC分类号： A61K38/20 ,  A61K38/17

    CPC分类号： A61K38/20 ,  A61K38/164 ,  A61K38/1709 ,  A61K38/1729 ,  A61K38/204 ,  A61K38/208 ,  A61K39/04 ,  A61K2300/00

    摘要： (Problems) To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same.(Means for Solving Problems) The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo expression vector and at least one interleukin selected from IL-6, IL-23 or IL-27, or a combination of 15K granulysin in vivo expression vector and HSP65DNA and IL-12DNA in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.

    摘要翻译： （问题）为了提供包含颗粒溶素作为活性成分的感染治疗剂，其副作用小，无细胞毒性，细菌几乎不能获得抗性，以及使用该治疗剂的治疗方法。 （解决问题的手段）本发明提供一种感染治疗剂，其包含15K颗粒溶素，15K颗粒溶素和15K颗粒溶素在体内表达载体的组合，15K颗粒溶素与至少一种选自IL- 6，IL-23或IL-27，15K颗粒溶素在体内表达载体和选自IL-6，IL-23或IL-27中的至少一种白介素或15K颗粒溶素的体内表达载体和HSP65DNA的组合的组合 和IL-12DNA体内表达载体，其对细菌的杀伤作用增强，副作用较小，细菌几乎不能获得抗性，以及使用其的处理方法。

    Therapeutic agent for infections, and treatment method using same
    6.
    发明授权
    Therapeutic agent for infections, and treatment method using same 有权
    用于感染的治疗剂和使用其的治疗方法

    公开(公告)号：US09233142B2

    公开(公告)日：2016-01-12

    申请号：US14292940

    申请日：2014-06-02

    申请人： NATIONAL HOSPITAL ORGANIZATION, KINKI-CHUO CHEST MEDICAL CENTER, partial interest ,  AZBIO CORPORATION, partial interest ,  Masaji Okada, partial interest ,  Yasushi Takamori, partial interest

    发明人： Masaji Okada ,  Yasushi Takamori ,  Kazuyuki Ogawa ,  Kinya Nagata

    IPC分类号： A61K38/20 ,  A61K39/04 ,  A61K38/16 ,  A61K38/17

    CPC分类号： A61K38/20 ,  A61K38/164 ,  A61K38/1709 ,  A61K38/1729 ,  A61K38/204 ,  A61K38/208 ,  A61K39/04 ,  A61K2300/00

    摘要： (Problems) To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same.(Means for Solving Problems) The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo expression vector and at least one interleukin selected from IL-6, IL-23 or IL-27, or a combination of 15K granulysin in vivo expression vector and HSP65DNA and IL-12DNA in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.

    摘要翻译： （问题）为了提供包含颗粒溶素作为活性成分的感染治疗剂，其副作用小，无细胞毒性，细菌几乎不能获得抗性，以及使用该治疗剂的治疗方法。 （解决问题的手段）本发明提供一种感染治疗剂，其包含15K颗粒溶素，15K颗粒溶素和15K颗粒溶素在体内表达载体的组合，15K颗粒溶素与至少一种选自IL- 6，IL-23或IL-27，15K颗粒溶素在体内表达载体和选自IL-6，IL-23或IL-27中的至少一种白介素或15K颗粒溶素的体内表达载体和HSP65DNA的组合的组合 和IL-12DNA体内表达载体，其对细菌的杀伤作用增强，副作用较小，细菌几乎不能获得抗性，以及使用其的处理方法。

    Human Th2 specific protein
    8.
    发明授权
    Human Th2 specific protein 失效
    人Th2特异性蛋白

    公开(公告)号：US6040426A

    公开(公告)日：2000-03-21

    申请号：US981825

    申请日：1998-05-11

    申请人： Kazuyuki Ogawa ,  Kazuya Tanaka ,  Kinya Nagata ,  Syoichi Takano

    发明人： Kazuyuki Ogawa ,  Kazuya Tanaka ,  Kinya Nagata ,  Syoichi Takano

    IPC分类号： A61K38/00 ,  C07K14/47 ,  C07K14/705 ,  C07K16/28 ,  C12N15/12 ,  C12P21/08 ,  C07K14/435

    CPC分类号： C07K16/28 ,  C07K14/47 ,  C07K14/705 ,  C07K14/70503 ,  A61K38/00

    摘要： The present invention provides for specifying the condition and type of immune-related diseases on the basis of the knowledge about the polarization of the distribution of helper T-cell subsets Th1 and Th2. More sepcifically, in this invention, the gene (B19) specific only the human Th2 is prepared and specified by a subtraction method, and a recombinant vector into which the gene is incorporated, a transformant transformed by the recombinant vector, a human-Th2-specific protein which the gene encodes and which derives from the transformant, and a monoclonal antibody against the Th2-specific protein are produced and the gene, protein, antibody, etc. are used as the means for specifying or correcting the polarization of the distribution of Th1 and Th2 to solve the above object.

    摘要翻译： PCT No.PCT / JP97 / 01906 Sec。 371日期：1998年5月11日 102（e）日期1998年5月11日PCT提交1997年6月5日PCT公布。 公开号WO97 / 46677 日期1997年12月11日本发明基于关于辅助T细胞亚群Th1和Th2的分布的极化的知识，提供免疫相关疾病的病症和类型的指定。 更具体地说，在本发明中，通过减法法制备和规定了仅具有人Th2的基因（B19），并且其中掺入了该基因的重组载体，由重组载体转化的转化体，人Th2- 产生基因编码并衍生自转化体的特异性蛋白质，并且产生针对Th2特异性蛋白质的单克隆抗体，并且使用基因，蛋白质，抗体等作为用于指定或校正分布的极化的手段 Th1和Th2解决上述目的。

    Human-Th1-specific protein, gene encoding the protein, transformants, recombinant vectors, and antibodies related to the gene
    9.
    发明授权
    Human-Th1-specific protein, gene encoding the protein, transformants, recombinant vectors, and antibodies related to the gene 失效
    人Th1特异性蛋白质，编码蛋白质的基因，转化体，重组载体和与该基因相关的抗体

    公开(公告)号：US5962319A

    公开(公告)日：1999-10-05

    申请号：US869793

    申请日：1997-06-05

    申请人： Kazuyuki Ogawa ,  Kazuya Tanaka ,  Kinya Nagata ,  Shoichi Takano

    发明人： Kazuyuki Ogawa ,  Kazuya Tanaka ,  Kinya Nagata ,  Shoichi Takano

    IPC分类号： C07K14/47 ,  C12N15/12 ,  C12N5/10

    CPC分类号： C07K14/47

    摘要： An element for specifying the condition and type of immune-related diseases on the basis of the knowledge about the polarization of distribution of Th1/Th2 subsets of helper T cells. The element for specifying or correcting the polarization of the Th1/Th2 subsets is implemented by use of a recombinant vector, a transformant, a human-Th1-specific protein, and an antibody which uses the human-Th1-specific protein as an antigen. A human-Th1-specific gene is prepared and specified by a subtraction technique and is incorporated into the recombinant vector. The transformant is formed by transforming the recombinant vector. The Th1-specific protein is encoded by the gene derived from the transformant.

    摘要翻译： 根据关于辅助T细胞Th1 / Th2亚型分布极化的知识，指定免疫相关疾病的病情和类型的要素。 通过使用重组载体，转化体，人Th1特异性蛋白质和使用人Th1特异性蛋白质作为抗原的抗体来实现用于指定或校正Th1 / Th2子集的极化的元件。 制备人Th1特异性基因并通过减法技术规定并且并入重组载体中。 通过转化重组载体形成转化体。 Th1特异性蛋白质由转化体衍生的基因编码。

    Method of identifying properties of substance with respect to human prostaglandin D2 receptors
    10.
    发明授权
    Method of identifying properties of substance with respect to human prostaglandin D2 receptors 有权
    识别物质相对于人类前列腺素D2受体的性质的方法

    公开(公告)号：US06884593B1

    公开(公告)日：2005-04-26

    申请号：US10069148

    申请日：2000-08-22

    申请人： Hiroyuki Hirai ,  Kazuyuki Ogawa ,  Kinya Nagata ,  Syoichi Takano

    发明人： Hiroyuki Hirai ,  Kazuyuki Ogawa ,  Kinya Nagata ,  Syoichi Takano

    IPC分类号： G01N33/88 ,  G01N33/53 ,  G01N33/567

    CPC分类号： G01N33/88 ,  G01N2500/04

    摘要： An object of the present invention is to provide a method of identifying a substance which acts on a newly found second human prostaglandin D2 receptor subtype that differs from the DP receptor, and is useful for treating or preventing various diseases. In order to attain the object, the present invention provides a method of identifying properties of a test substance with respect to a human prostaglandin D receptor, by establishing correlation between the effect of a test substance on human CRTH2 with the effect of the test substance on the human prostaglandin D receptor.

    摘要翻译： 本发明的目的是提供一种鉴定作用于新发现的与DP受体不同的第二人前列腺素D 2受体亚型的物质的方法，并且可用于治疗或预防各种 疾病 为了达到上述目的，本发明提供了一种鉴定被测物质相对于人前列腺素D受体的性质的方法，其特征在于，测试物质对人CRTH2的作用与受检物质对 人类前列腺素D受体。